Logo image of ACHL

ACHILLES THERAPEUTICS PL-ADR (ACHL) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ACHL - US00449L1026 - ADR

1.48 USD
+0.01 (+0.68%)
Last: 3/20/2025, 8:00:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ACHL. ACHL was compared to 529 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ACHL as it has an excellent financial health rating, but there are worries on the profitability. ACHL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ACHL had negative earnings in the past year.
ACHL had a negative operating cash flow in the past year.
ACHL had negative earnings in each of the past 5 years.
In the past 5 years ACHL always reported negative operating cash flow.
ACHL Yearly Net Income VS EBIT VS OCF VS FCFACHL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -54.52%, ACHL perfoms like the industry average, outperforming 44.91% of the companies in the same industry.
ACHL's Return On Equity of -64.84% is in line compared to the rest of the industry. ACHL outperforms 58.25% of its industry peers.
Industry RankSector Rank
ROA -54.52%
ROE -64.84%
ROIC N/A
ROA(3y)-31.57%
ROA(5y)-24.64%
ROE(3y)-35.39%
ROE(5y)-27.5%
ROIC(3y)N/A
ROIC(5y)N/A
ACHL Yearly ROA, ROE, ROICACHL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -10 -20 -30 -40 -50

1.3 Margins

ACHL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACHL Yearly Profit, Operating, Gross MarginsACHL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for ACHL has been increased compared to 1 year ago.
ACHL has more shares outstanding than it did 5 years ago.
ACHL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ACHL Yearly Shares OutstandingACHL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
ACHL Yearly Total Debt VS Total AssetsACHL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

ACHL has an Altman-Z score of -2.60. This is a bad value and indicates that ACHL is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ACHL (-2.60) is comparable to the rest of the industry.
ACHL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.6
ROIC/WACCN/A
WACCN/A
ACHL Yearly LT Debt VS Equity VS FCFACHL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

ACHL has a Current Ratio of 6.04. This indicates that ACHL is financially healthy and has no problem in meeting its short term obligations.
ACHL has a Current ratio of 6.04. This is in the better half of the industry: ACHL outperforms 63.86% of its industry peers.
A Quick Ratio of 6.04 indicates that ACHL has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.04, ACHL is in the better half of the industry, outperforming 64.39% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.04
Quick Ratio 6.04
ACHL Yearly Current Assets VS Current LiabilitesACHL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

ACHL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.70%, which is quite good.
EPS 1Y (TTM)12.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ACHL will show a small growth in Earnings Per Share. The EPS will grow by 0.30% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y89.45%
EPS Next 2Y38.91%
EPS Next 3Y-17.11%
EPS Next 5Y0.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACHL Yearly Revenue VS EstimatesACHL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2031 20M 40M 60M 80M
ACHL Yearly EPS VS EstimatesACHL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ACHL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACHL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACHL Price Earnings VS Forward Price EarningsACHL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACHL Per share dataACHL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A cheap valuation may be justified as ACHL's earnings are expected to decrease with -17.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.91%
EPS Next 3Y-17.11%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACHL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACHILLES THERAPEUTICS PL-ADR

NASDAQ:ACHL (3/20/2025, 8:00:00 PM)

1.48

+0.01 (+0.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)04-02 2025-04-02/amc
Inst Owners86.1%
Inst Owner Change0%
Ins Owners6.51%
Ins Owner ChangeN/A
Market Cap63.20M
Revenue(TTM)N/A
Net Income(TTM)-66.88M
Analysts40
Price Target6.12 (313.51%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.41%
Min EPS beat(2)-14.78%
Max EPS beat(2)1.96%
EPS beat(4)2
Avg EPS beat(4)-46.83%
Min EPS beat(4)-211.02%
Max EPS beat(4)36.52%
EPS beat(8)3
Avg EPS beat(8)-30.26%
EPS beat(12)6
Avg EPS beat(12)-14.42%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.26%
EPS NY rev (1m)0%
EPS NY rev (3m)88.54%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.61
P/tB 0.61
EV/EBITDA N/A
EPS(TTM)-1.65
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)-1.5
FCFYN/A
OCF(TTM)-1.48
OCFYN/A
SpS0
BVpS2.42
TBVpS2.42
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -54.52%
ROE -64.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.57%
ROA(5y)-24.64%
ROE(3y)-35.39%
ROE(5y)-27.5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.12%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.04
Quick Ratio 6.04
Altman-Z -2.6
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)152.93%
Cap/Depr(5y)462.21%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
EPS Next Y89.45%
EPS Next 2Y38.91%
EPS Next 3Y-17.11%
EPS Next 5Y0.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y8.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.37%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.14%
OCF growth 3YN/A
OCF growth 5YN/A

ACHILLES THERAPEUTICS PL-ADR / ACHL FAQ

What is the fundamental rating for ACHL stock?

ChartMill assigns a fundamental rating of 3 / 10 to ACHL.


What is the valuation status for ACHL stock?

ChartMill assigns a valuation rating of 0 / 10 to ACHILLES THERAPEUTICS PL-ADR (ACHL). This can be considered as Overvalued.


What is the profitability of ACHL stock?

ACHILLES THERAPEUTICS PL-ADR (ACHL) has a profitability rating of 1 / 10.


What is the financial health of ACHILLES THERAPEUTICS PL-ADR (ACHL) stock?

The financial health rating of ACHILLES THERAPEUTICS PL-ADR (ACHL) is 7 / 10.


What is the expected EPS growth for ACHILLES THERAPEUTICS PL-ADR (ACHL) stock?

The Earnings per Share (EPS) of ACHILLES THERAPEUTICS PL-ADR (ACHL) is expected to grow by 89.45% in the next year.